arXiv:2602. 02124v2 Announce Type: replace-cross Abstract: Drug-induced toxicity is a leading cause of preclinical and early-clinical failure, making early detection critical.
By Olga Graf, Dhrupal Patel, Peter Gro{\ss}, Charlotte Lempp, Matthias Hein, Fabian Heinemann
arXiv:2606. 28392v1 Announce Type: cross Abstract: Accurate lesion segmentation in PET/CT is critical for oncology, yet remains challenging because physiologic tracer uptake and artifacts can mimic malignant signal.
By Jiasheng Wang, Tanun Jitwatcharakomol, Piyawadee Jongpradubgiat, Simeng Zhu
HERO (Histology Encoder for Robust Representation in Oncology) is a ViT‑G/14 pathology foundation model trained with DINO and iBOT objectives and refined using high‑resolution Gram anchoring on a 500‑million‑tile corpus from about 575,000 clinical whole‑slide images. It demonstrates superior robustness to center, scanner, and stain variation compared to other state‑of‑the‑art foundation models, while maintaining competitive performance on tile‑level classification, segmentation, and gene‑expression prediction. Across 39 slide‑level clinical tasks, HERO ranks first on average and achieves the best average rank across six benchmark frameworks under an equal‑weighted analysis.
By Zhi Li (Caris Life Sciences, Irving, TX, United States), Eghbal Amidi (Caris Life Sciences, Irving, TX, United States), Yating Cheng (Caris Life Sciences, Irving, TX, United States), Tyson Dawson (Caris Life Sciences, Irving, TX, United States), Gorkem Can Ates (Caris Life Sciences, Irving, TX, United States), Shuzhen Kuang (Caris Life Sciences, Irving, TX, United States), Norsang Lama (Caris Life Sciences, Irving, TX, United States), Md Ashequr Rahman (Caris Life Sciences, Irving, TX, United States), Zhiying Lu (Caris Life Sciences, Irving, TX, United States), Elisabeth K. Kong (Caris Life Sciences, Irving, TX, United States), Milan Radovich (Caris Life Sciences, Irving, TX, United States), David Spetzler (Caris Life Sciences, Irving, TX, United States), Matthew Oberley (Caris Life Sciences, Irving, TX, United States), George W. Sledge (Caris Life Sciences, Irving, TX, United States), Ming Chen (Caris Life Sciences, Irving, TX, United States)
Pathology vision-language models (VLMs) have recently progressed rapidly and are commonly evaluated by answer accuracy on pathology VQA benchmarks. However, we dig into current evaluations and identify three overlooked issues: 1) Visual evidence is not always necessary.
arXiv:2409.16183v2 Announce Type: replace
Abstract: Radiology is a vital and complex component of modern clinical workflow and covers many tasks. Recently, vision-language (VL) foundation models in m...
By Xiaohong Liu, Guoxing Yang, Yulin Luo, Jiaji Mao, Xiang Zhang, Haibo Wang, Zhiyang He, Ming Gao, Shanghang Zhang, Jun Shen, Guangyu Wang
arXiv:2609.00866v1 Announce Type: cross
Abstract: The rapid advancement of vision-language models (VLMs) has accelerated progress in computational pathology; however, whole-slide image (WSI)-based pa...
By Yumi Lee, Harim Oh, Hyoryung Kim, Minji Kim, Eunsu Kim, Hyeseong Lee, Junya Fukuoka, Andrey Bychkov, Jijgee Munkhdelger, Rajiv Kumar Kaushal, Ayushi Sahay, Rajni Yadav, Bharathi Prabakaran, Sulen Sarioglu, Serdar Balc{\i}, Ilknur Turkmen, Yuri Tolkach, Christian Harder, Julian Westerdorf, Reinhard Buettner, Audun Ljone Henriksen, Sepp De Raedt, Byung Hyun Lee, Sungjin Lim, Joohoon Lee, Gwanghyun Kim, Se Young Chun, Suryakant Singh, Saarthak Kapse, Prateek Prasanna, Kyung A Kim, Yousun Kang, Sehwan Yoo, Sungman Hong, Shubham Innani, Michael Feldman, Spyridon Bakas, Ujjwal Baid, Prasad Dutande, Suhas Gajare, Bhakti Baheti, Serkan S\"okmen, Ece Tu\u{g}ba Cebeci, Ahmet Hal{\i}c{\i}, Musa Balc{\i}, Kardelen Pe\c{c}enek, Srividhya Sainath, Kyongseok Jang, Messi H. J. Lee, Noorul Wahab, Bodong Du, Jiaming Zhang, Qixiang Zhang, Jang-Hwan Choi, Sangjeong Ahn